CS
BCTXL

Clear Street’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Clear Street’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.7K Hold
104,196
– – ﹤0.01% 840
2026
Q1 		$107K Buy
+104,196
New +$110K ﹤0.01% 612

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Clear Street's BCTXL Position: Q2 2026 in Review

Clear Street held its BriaCell Therapeutics Warrant (BCTXL) position steady in Q2 2026 at 104,196 shares worth $92.7K. The position accounts for ﹤0.01% of the portfolio, ranked #840.

Clear Street first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $107K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Clear Street held 104,196 shares of BriaCell Therapeutics Warrant worth $92.7K as of Q2 2026.
  • Clear Street left its BriaCell Therapeutics Warrant share count unchanged in Q2 2026.
  • BriaCell Therapeutics Warrant made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #840 holding.
  • Clear Street first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Clear Street's BriaCell Therapeutics Warrant position peaked at $107K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.